Trimetrexate Glucuronate
CI 898 dihydrochloride · CI 898 TRIHYDROCHLORIDE · Trimetrexate glucuronate · CI 898 D-Glucuronic Acid Salt (Trimetrexate D-Glucuronic Acid Salt) · 5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]quinazoline-2,4-diamine D-glucuronate · 5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediaminetrihydrochloride
Identifikatoren & physikalische Daten
| CAS No. | 82952-64-5 |
|---|---|
| Summenformel | C25H33N5O10 |
| Durchschnittliche Molmasse | 563,6 g/mol |
| Monoisotopische Masse | 563,22274227 g/mol |
| SMILES | COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)O |
| InChIKey | ZCJXQWYMBJYJNB-LRDBBFHQSA-N |
| PubChem CID | 54949 |
| ChEMBL | CHEMBL2218878 |
| EC No. | 692-446-3 |
| DTXSID | DTXSID90273968 |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 253 |
|---|---|
| H-Brücken-Donoren | 8 |
| H-Brücken-Akzeptoren | 15 |
| Frei drehbare Bindungen | 11 |
| Schwere Atome | 40 |
| Formalladung | 0 |
| Komplexität | 648 |
| Human Drugs | FDA approved drugs -> Active ingredient |
| Lagerbedingungen | Store at -20°C |
| Aggregatzustand | Solid |
| Farbe | Off-white to light yellow |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]P203, P280, P318, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Regulatorische Informationen | Hazard Traits - Developmental Toxicity |
| Hazard Classes and Categories | Repr. 2 (100%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Trimetrexate glucuronateAmbiguous-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| Alarmwort | Warnung |
| Gefahrenhinweise | Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H361 |
Anwendungen & Verwendung
Beschreibung
Trimetrexate glucuronate is a nonclassical antifolate introduced in the U.S.A. and Canada as second-line therapy for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis in AIDS patients who are refractory or intolerant to co-trimoxazole therapy. Trimetrexate glucuronate is reportedly to be in clinical trials for the treatment of several types of cancer including colorectal, gastric, pancreas, prostate, bladder, lung, breast, head, and neck cancers. It is also in early clinical trials for topical use in treating psoriasis and as an oral drug to treat rheumatoid arthritis. The mechanism of action of trimetrexate glucuronate is via inhibition of the enzyme dihydrofolate reductase which mediates the reduction of dihydrofolate to tetrahydrofolic acid and results in disruption of DNA, RNA and protein synthesis, with consequent cell death. Due to its toxicity to bone marrow and the GI tract, trimetrexate glucuronate must be concurrently administered with leucovorin as a rescue agent.
Verwenden
Antineoplastic.